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Abstract
Background: The GOOD (Global Cardiometabolic Risk Profile in Patients with Hypertension
Disease) survey showed that blood pressure control was significantly worse in hypertensive
patients with metabolic syndrome and/or diabetes mellitus than in those with essential
hypertension only. This analysis aimed to investigate which components of the metabolic syndrome
are primarily associated with poor blood pressure control.
Methods: The GOOD survey was designed as an observational cross-sectional survey in 12
European countries to assess the cardiometabolic risk profile in patients with essential
hypertension. Investigators were randomly selected from a list of general practitioners (70% of
investigators) and a list of specialists such as internists, cardiologists and hypertension specialists
(30% of investigators). Data from 3,280 outpatients with hypertension, aged at least 30 years who
were receiving antihypertensive treatment or had newly diagnosed hypertension according to the
European Society of Hypertension and the European Society of Cardiology criteria, were included
in the analyses. Blood pressure control, body mass index (BMI), waist circumference, serum
triglycerides, total and high density lipoprotein (HDL) cholesterol measurements were compared
in patients with diabetes mellitus and metabolic syndrome, with diabetes mellitus only, with
metabolic syndrome only, and with neither metabolic syndrome nor diabetes mellitus.
Results: The highest blood pressure values were found in patients with metabolic syndrome with
or without diabetes mellitus. Blood pressure was significantly lower in patients with diabetes
mellitus only. The highest BMI, waist circumference and serum triglycerides, and the lowest HDL
cholesterol levels among the groups studied occurred in patients with metabolic syndrome, either
with or without diabetes mellitus.
Conclusion: Among the components of the metabolic syndrome, it is not impaired glucose
tolerance which is associated with the poor response to antihypertensive treatment. Instead,
visceral obesity and dyslipidemia components of the metabolic syndrome, i.e. hypertriglyceridemia
and low HDL cholesterol levels, are associated with resistance to antihypertensive treatment.
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Background
In a previous paper, in which the principal results of the
Global Cardiometabolic Risk Profile in Patients with
Hypertension Disease (GOOD) survey were reported, the
main finding was that blood pressure control was signifi-
cantly worse in hypertensive patients with diabetes melli-
tus and/or metabolic syndrome [1]. The prevalence of
metabolic syndrome and type 2 diabetes was significantly
higher in patients with uncontrolled blood pressure com-
pared with those with controlled blood pressure. Ninety
five percent of patients with both metabolic syndrome
and type 2 diabetes had uncontrolled blood pressure. Dia-
betes mellitus and metabolic syndrome present with
partly overlapping features. Of note, patients with meta-
bolic syndrome without diabetes mellitus were associated
with a similarly poor blood pressure control as those with
diabetes mellitus. The components of the metabolic syn-
drome, besides hypertension, are impaired glucose toler-
ance, dyslipidemia and obesity, especially central obesity,
as measured by waist circumference. Therefore, in view of
the principal results of the GOOD survey, we aimed to
investigate which components of the metabolic syndrome
are primarily associated with poor blood pressure control.
Methods
The GOOD survey was designed as an observational cross-
sectional survey in 12 European countries to assess the
cardiometabolic risk profile in patients with essential
hypertension [1]. The study was conducted in Belgium,
Germany, Hungary, Italy, the Netherlands, Norway, Por-
tugal, Slovenia, Spain, Sweden, Turkey and the United
Kingdom between 6 October, 2006 and 16 May, 2007.
Investigators were randomly selected from a list of general
practitioners (70% of investigators) and a list of specialists
such as internists, cardiologists and hypertension special-
ists (30% of investigators). The lists contained 3- to 10-
fold the number of investigators needed.
The first patient to be seen by physicians each working day
who fulfilled the inclusion criteria were asked to partici-
pate. In the case of decline the next patient was asked to
participate. Maximally two patients per day were
recruited. Further details of the selection procedure have
been published earlier [1].
Patients included in the survey were outpatients with
hypertension, aged at least 30 years, who were receiving
antihypertensive treatment or had newly diagnosed
hypertension according to the European Society of Hyper-
tension and European Society of Cardiology (ESH/ESC)
criteria [2,3], which was confirmed on the day of inclu-
sion in the study.
Exclusion criteria were pregnancy, menstruation, hospi-
talization, secondary hypertension, fever, known renal
disease (serum creatinine > 177 μmol/l) and current drug
treatment and/or concomitant conditions that could
affect microalbuminuria measurements.
Data collection
The following data were collected during the patients' vis-
its: weight, height, waist circumference, seated blood pres-
sure (two measurements taken after at least 3 minutes'
rest), heart rate at rest, urinary albumin excretion, cardi-
ometabolic risk factors, including duration of hyperten-
sion, history of diabetes, cardiovascular disease or stroke,
lifestyle factors including alcohol consumption, physical
exercise and smoking habits, and laboratory measure-
ments of fasting blood glucose, fasting lipid profile and
serum creatinine. Furthermore, data on current antihyper-
tensive medications, other cardiovascular, antithrom-
botic, lipid, glucose and uric acid-lowering drugs were
collected. Patients with incomplete records were not
excluded. Metabolic syndrome was diagnosed according
to the National Cholesterol Education Program Adult
Treatment Panel III (ATP III) criteria [4], i.e. at least three
of the following had to be present: blood pressure ≥ 130/
85 mmHg; waist circumference ≥ 102 cm (men) or ≥ 88
cm (women); triglycerides ≥ 1.69 mmol/l or on drug treat-
ment for elevated triglycerides; HDL cholesterol < 1.03
mmol/l (men) or < 1.29 mmol/l (women) or on drug
treatment for reduced HDL cholesterol; fasting glucose ≥
5.55 mmol/l or on drug treatment for elevated glucose. In
this study, history or treatment of hypertension were not
counted as criteria for metabolic syndrome as they
applied to all patients.
The study was conducted in accordance with the princi-
ples laid down by the 18th World Medical Assembly (Hel-
sinki, 1964) and all subsequent amendments. The study
was also conducted in accordance with the European
guidelines for Good Epidemiology Practice (GEP), and
Proper Conduct in Epidemiologic Research (European
Federation, IEA and "societies", 2004). Each participating
country ensured that all necessary regulatory submissions
(e.g., IRB/IEC) were performed in accordance with local
regulations including local data protection regulations.
Statistics
Among the hypertensive patients studied, four groups
were compared: patients with metabolic syndrome and
diabetes mellitus, with metabolic syndrome but no diabe-
tes mellitus, with diabetes mellitus but no metabolic syn-
drome, and with neither diabetes mellitus nor metabolic
syndrome. The haemodynamic, clinical and metabolic
parameters were tested for significance using analysis of
variance with Tukey's test as a post-hoc test.Cardiovascular Diabetology 2009, 8:51 http://www.cardiab.com/content/8/1/51
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Results
In total, 3,464 outpatients were recruited in the survey
and of these 3,280 were included in these analyses. The
regional distribution of the patients has been described
earlier [2]. Figure 1 and Table 1 show systolic blood pres-
sure in hypertensive patients with metabolic syndrome (n
= 1033), with diabetes mellitus (n = 206), with both (n =
864), and with none of these (n = 1177). Systolic blood
pressure was highest in patients with metabolic syndrome
with or without diabetes mellitus. Furthermore, systolic
blood pressure was significantly higher in patients with
metabolic syndrome only, than in patients with diabetes
mellitus only.
Similar findings were obtained with diastolic blood pres-
sure (Figure 2, Table 1). Diastolic blood pressure was sig-
nificantly higher in patients with metabolic syndrome
alone, than in those with only diabetes mellitus. Moreo-
ver, patients with metabolic syndrome only showed a
higher diastolic blood pressure than those with metabolic
syndrome and diabetes mellitus.
The number of different antihypertensive therapies the
patients were receiving is shown in Table 2. The percent-
age of patients receiving 1, 2 or ≥3 different treatments
was similar in those with metabolic syndrome alone and
in those with diabetes alone, with 34.4% and 38.8%,
respectively, receiving ≥3 treatments. More patients
(48.4%) with metabolic syndrome and diabetes, and
fewer (28.0%) with neither metabolic syndrome nor dia-
betes were receiving ≥3 treatments.
The next question to arise was which component of the
metabolic syndrome, except blood glucose, may be asso-
ciated with blood pressure. Figure 3 and Table 1 show
body mass index (BMI) depending on the presence or
absence of metabolic syndrome and diabetes mellitus.
BMI was higher in patients with metabolic syndrome and
diabetes than in those with metabolic syndrome alone.
BMI in patients with metabolic syndrome only was signif-
icantly higher than in those with diabetes mellitus alone.
Waist circumference was highest in patients with meta-
bolic syndrome whether or not they had concomitant dia-
betes mellitus. Patients with diabetes mellitus alone
showed significantly lower waist circumference than
those with metabolic syndrome alone (Figure 4, Table 1).
Next, we examined the lipid parameters obtained for their
association with diabetes mellitus and the metabolic syn-
drome. Figure 5 and Table 1 show serum triglycerides,
total and HDL cholesterol levels depending on the pres-
ence or absence of metabolic syndrome and diabetes mel-
litus. Serum triglycerides were highest in patients with
metabolic syndrome with diabetes mellitus. Patients with
metabolic syndrome only, had significantly higher serum
triglycerides than patients with diabetes mellitus only
(Figure 5A, Table 1). Similarly, serum cholesterol was
highest in patients with metabolic syndrome only,
whereas patients with diabetes mellitus only, had the low-
est serum cholesterol (Figure 5B, Table 1). Serum HDL
cholesterol levels showed a pattern largely inverse to that
of serum triglycerides, with the lowest levels in patients
with metabolic syndrome, either with or without diabetes
mellitus, which were significantly lower than in patients
Systolic blood pressure (mean ± SD) in patients with metabolic syndrome, but no diabetes mellitus (MS ∅DM), with metabolic  syndrome and diabetes mellitus (MS+DM), with neither metabolic syndrome nor diabetes mellitus (∅MS ∅DM), and with dia- betes mellitus only (∅MS DM); *** p < 0.001 Figure 1
Systolic blood pressure (mean ± SD) in patients with metabolic syndrome, but no diabetes mellitus (MS 
∅DM), with metabolic syndrome and diabetes mellitus (MS+DM), with neither metabolic syndrome nor diabe-
tes mellitus (∅MS ∅DM), and with diabetes mellitus only (∅MS DM); *** p < 0.001.Cardiovascular Diabetology 2009, 8:51 http://www.cardiab.com/content/8/1/51
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with diabetes mellitus but no metabolic syndrome (Figure
5C, Table 1). Thus, the lipid parameters studied showed a
similar pattern to those of systolic and diastolic blood
pressure among the four groups of patients.
Discussion
The findings show that blood pressure is influenced by the
metabolic syndrome, irrespective of the presence or
absence of diabetes mellitus. This finding was not a reflec-
tion of the antihypertensive treatments received by the
patients, as those with metabolic syndrome alone and
those with diabetes alone were receiving a similar number
of treatments. Other factors may be more important for
conferring resistance to antihypertensive treatment, since
patients with diabetes mellitus alone, without accompa-
nying metabolic syndrome, showed much lower blood
pressure than patients with metabolic syndrome with or
without diabetes mellitus. In addition, resistance to anti-
hypertensive treatment may also reflect some doubts
about target blood pressure values and low physician
compliance in prescribing further therapy for patients
with metabolic syndrome[1].
As disturbed glucose metabolism is present in both meta-
bolic syndrome and diabetes mellitus, other factors of the
metabolic syndrome are likely to be responsible for the
tendency towards higher blood pressure in patients with
metabolic syndrome. Indeed, when we evaluated the
other components of the metabolic syndrome with
respect to their impact on blood pressure, it was BMI and
Table 1: Systolic and diastolic blood pressure (P sys, P dia), body mass index (BMI), waist circumference and serum lipids (mean ± SD) 
in the different groups studied. 
MS ∅DM MS + DM ∅MS ∅DM ∅MS DM
P sys (mm Hg) 145 ± 17 144 ± 16 139 ± 17 137 ± 18
P dia (mm Hg) 87 ± 10 83 ± 9 83 ± 10 80 ± 10
BMI (kg/m2) 30,7 ± 4,6 31,7 ± 4,9 27,2 ± 4,1 27,6 ± 4,4
Waist circumference (cm) 108,2 ± 11,5 110,5 ± 13,2 98,2 ± 10,0 97,6 ± 9,8
Total cholesterol (mmol/l) 5,52 ± 0,03 5,17 ± 0,04 5,33 ± 0,03 4,87 ± 0,08
Triglycerides (mmol/l) 2,12 ± 0,03 2,25 ± 0,03 1,29 ± 0,03 1,24 ± 0,06
HDL cholesterol (mmol/l) 1,25 ± 0,01 1,20 ± 0,01 1,55 ± 0,01 1,47 ± 0,03
For significance levels and abbreviations see Figs. 1-5)
Diastolic blood pressure (mean ± SD) in patients with metabolic syndrome, but no diabetes mellitus (MS ∅DM), with meta- bolic syndrome and diabetes mellitus (MS+DM), with neither metabolic syndrome nor diabetes mellitus (∅MS ∅DM), and with  diabetes mellitus only (∅MS DM); *** p < 0.001 Figure 2
Diastolic blood pressure (mean ± SD) in patients with metabolic syndrome, but no diabetes mellitus (MS 
∅DM), with metabolic syndrome and diabetes mellitus (MS+DM), with neither metabolic syndrome nor diabe-
tes mellitus (∅MS ∅DM), and with diabetes mellitus only (∅MS DM); *** p < 0.001.Cardiovascular Diabetology 2009, 8:51 http://www.cardiab.com/content/8/1/51
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waist circumference which showed the closest association
with blood pressure, both systolic and diastolic. On the
other hand, the presence or absence of diabetes mellitus
was not a major determinant of blood pressure. The above
analyses were based on blood pressure values instead of
blood pressure control rates. This seemed appropriate
since blood pressure control rates were much lower in
patients with diabetes mellitus than in patients with met-
abolic syndrome due to the fact that in patients with met-
abolic syndrome without diabetes mellitus the blood
pressure target was < 140/90 mm Hg, but in patients with
diabetes mellitus with or without metabolic syndrome the
blood pressure target was < 130/80 mm Hg. Due to the
different blood pressure targets, blood pressure control
rates differed markedly depending on the presence or
absence of diabetes mellitus.
These findings suggest that among the components of the
metabolic syndrome, it is central obesity which affects
blood pressure most. These findings are in line with the
newer concepts on the pathophysiology of hypertension.
The role of adipocytokines in the pathogenesis of hyper-
tension has been of increasing interest in the last decade,
and has markedly extended our view on the humoral
mechanisms of hypertension [3-6]. Among the adipocy-
tokines involved in the pathogenesis of hypertension, adi-
ponectin and leptin have been most extensively studied.
Recently, in a 5-year prospective study, serum adiponectin
levels have been shown to be independent predictors of
Table 2: Number of antihypertensive therapies received by patients according to the presence or absence of metabolic syndrome and 
diabetes. 
ABCD
Number of different 
antihypertensive 
therapies
Metabolic syndrome 
but no diabetes a,b
(%)
Metabolic syndrome 
and diabetes b
(%)
No metabolic syn-
drome or diabetes c
(%)
No metabolic 
syndrome but diabetes
(%)
0 1.1 0.1 0.3 0.5
1 29.3 21.4 31.5 27.7
2 35.3 30.3 36.5 32.0
≥3 34.4 48.4 28.0 38.8
a: p < 0.01 vs. B; b: p < 0.01 vs. C; c: p < 0.05 vs. D. The other intergroup differences were not significant by the Chi square test
BMI (mean ± SD) in patients with metabolic syndrome, but no diabetes mellitus (MS ∅DM), with metabolic syndrome and dia- betes mellitus (MS+DM), with neither metabolic syndrome nor diabetes mellitus (∅MS ∅DM), and with diabetes mellitus only  (∅MS DM); *** p < 0.001 Figure 3
BMI (mean ± SD) in patients with metabolic syndrome, but no diabetes mellitus (MS ∅DM), with metabolic 
syndrome and diabetes mellitus (MS+DM), with neither metabolic syndrome nor diabetes mellitus (∅MS 
∅DM), and with diabetes mellitus only (∅MS DM); *** p < 0.001.Cardiovascular Diabetology 2009, 8:51 http://www.cardiab.com/content/8/1/51
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incident hypertension in a population normotensive at
baseline [7].
Adiponectin, besides its effects on insulin sensitivity, may
also act on the vasculature directly. Hypoadiponectinemia
was found to be associated with an impaired endothe-
lium-dependent vasodilation in humans and mice [8-10].
Conversely, adiponectin is a stimulator of nitric oxide
(NO) production in endothelial cells [11,12]. In addition
to adiponectin, other adipocytokines, such as leptin, have
also been linked with the development of hypertension.
Leptin increases peripheral sympathetic tone, and leptin-
deficient mice show lower arterial blood pressure [13,14].
Among the many known adipocytokines, angiotensino-
gen has been found to be produced by adipocytes, and
angiotensinogen can promote the development of hyper-
tension by stimulating the production of angiotensin II
[15,16].
There is also ample epidemiological evidence that obesity
is one of the major causes of essential hypertension.
Excess weight gain has been repeatedly shown to be one
of the best predictors for the development of hypertension
[17-19]. Moreover, from the Framingham Heart study it
has been estimated that about 65% to 75% of the risk for
hypertension can be attributed to excess weight [20].
Recent results from the National Health and Nutrition
Examination Survey (NHANES) support the eminent role
of obesity in the development of hypertension [21]:
between NHANES II (1988-1994) and NHANES 1999-
2004, the age-standardized hypertension prevalence
increased from 24.4% to 28.9%. Depending on gender
and ethnicity, between 20% and 80% of this increase
could be attributed to increasing BMI. Although the
authors did not report control rates depending on BMI,
blood pressure distribution within the population was
shifted towards higher values with increasing BMI.
The relative contributions of subcutaneous and visceral fat
to the development of hypertension have been elucidated
in further studies. It is visceral fat which has been identi-
fied as the more prominent factor inducing hypertension
[22]: quantification of adipose tissue in different locations
by computer tomography revealed that, in a group of 300
Japanese Americans, the amount of visceral fat, but not
subcutaneous fat, conferred a risk of incident hyperten-
sion during the follow-up of up to 11 years.
Blood pressure is also associated with humoral compo-
nents of the metabolic syndrome. Low HDL levels are
known to confer an increased cardiovascular risk. Moreo-
ver, a direct association between low serum HDL levels
and blood pressure has been shown in elderly hyperten-
sive patients [23]. The mechanistic background of this
association may be that HDL contains important lipid
mediators such as sphingosine-1-phosphate, sphingosyl-
phosphorylcholine, and lysosulphatide which induce
NO-dependent vasorelaxation via the lysophospholipid
receptor S1P3 [24]. Thereby HDL restores endothelial
function by improving NO availability and hence favours
vasorelaxation.
As in the present survey we studied patients receiving anti-
hypertensive treatment, the results do not imply a higher
prevalence of hypertension with increasing BMI, but show
less effective blood pressure control in obese patients.
This finding infers that in obesity-related hypertension
Waist circumference (mean ± SD) in patients with metabolic syndrome, but no diabetes mellitus (MS ∅DM), with metabolic  syndrome and diabetes mellitus (MS+DM), with neither metabolic syndrome nor diabetes mellitus (∅MS ∅DM), and with dia- betes mellitus only (∅MS DM); *** p < 0.001 Figure 4
Waist circumference (mean ± SD) in patients with metabolic syndrome, but no diabetes mellitus (MS ∅DM), 
with metabolic syndrome and diabetes mellitus (MS+DM), with neither metabolic syndrome nor diabetes mel-
litus (∅MS ∅DM), and with diabetes mellitus only (∅MS DM); *** p < 0.001.Cardiovascular Diabetology 2009, 8:51 http://www.cardiab.com/content/8/1/51
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Serum lipids (mean ± SD; A: triglycerides, B: total cholesterol, C: HDL cholesterol) in patients with metabolic syndrome, but  no diabetes mellitus (MS ∅DM), with metabolic syndrome and diabetes mellitus (MS+DM), with neither metabolic syndrome  nor diabetes mellitus (∅MS ∅DM), and with diabetes mellitus only (∅MS DM); *** p < 0.001 Figure 5
Serum lipids (mean ± SD; A: triglycerides, B: total cholesterol, C: HDL cholesterol) in patients with metabolic 
syndrome, but no diabetes mellitus (MS ∅DM), with metabolic syndrome and diabetes mellitus (MS+DM), 
with neither metabolic syndrome nor diabetes mellitus (∅MS ∅DM), and with diabetes mellitus only (∅MS 
DM); *** p < 0.001.Cardiovascular Diabetology 2009, 8:51 http://www.cardiab.com/content/8/1/51
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other pathogenetic mechanisms may be involved than
occur in other forms of essential hypertension.
The data in this survey show that metabolic syndrome is
not only associated with higher blood pressure but also
with the poor response to treatment. Interestingly, among
the components of the metabolic syndrome, it is not
impaired glucose tolerance which is associated with the
response to antihypertensive treatment. Instead, both vis-
ceral obesity and the dyslipidemia of the metabolic syn-
drome, i.e. hypertriglyceridemia and low HDL cholesterol
levels, are associated with resistance to antihypertensive
treatment.
There have been few studies addressing the relative contri-
butions of single components of the metabolic syndrome
to the development of hypertension and vascular disease
[25]. The GOOD registry offers an appropriate database to
answer these questions. Earlier publications of the GOOD
data focused on the control of blood pressure depending
on the co-occurrence of the metabolic syndrome [1] and
on regional differences in blood pressure control [2]. The
DIG study addressed a similar question as the present
study; Hanefeld et al. [26] studied the relative contribu-
tions of the different components of the metabolic syn-
drome to the development of atherosclerotic vascular
disease. In contrast to the present study, the DIG study did
not assess the impact of the components of the metabolic
syndrome on the development of hypertension. Similarly
to the present study, diabetes mellitus alone did not con-
tribute significantly to the development of atherosclerotic
vascular disease, whereas the combination of diabetes
mellitus with hypertension and dyslipidemia was closely
associated with vascular disease.
Conclusion
Among the components of the metabolic syndrome,
impaired glucose tolerance is not associated with the poor
response to antihypertensive treatment. Instead, other
components of the metabolic syndrome, viz. visceral
obesity and dyslipidemia, hypertriglyceridemia and low
HDL cholesterol levels, are associated with resistance to
antihypertensive treatment.
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